| $337M | ||
| $259M | ||
| $79M | ||
| $60M | ||
| $58M | ||
| $50M |
Buys | $0 | 0 | – |
Sells | $0 | 0 | – |
Kyverna Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing cell therapies for patients suffering from autoimmune diseases. Its lead product candidate is KYV-101, an autologous CD19 CAR T-cell product candidate for the treatment of patients with lupus nephritis and systemic sclerosis that is in Phase I clinical trial; and for myasthenia gravis and multiple sclerosis that is in Phase II clinical trial. The company is also developing KYV-201, an allogeneic CD19 CAR T-cell product candidate that is in preclinical stage to treat multiple autoimmune diseases. In addition, it is developing product candidates to treat other autoimmune diseases, such as inflammatory bowel disease that includes Crohn's disease and ulcerative colitis. Kyverna Therapeutics, Inc. has a license and collaboration agreement with Intellia Therapeutics, Inc. to research and develop an allogeneic CD19-directed CAR cell therapy product; and with Kite to research and develop programs for the treatment, diagnosis, and prevention of autoimmune, inflammatory, and allogeneic stem cell transplant inflammatory diseases. The company was formerly known as BAIT Therapeutics, Inc. and changed its name to Kyverna Therapeutics, Inc. in October 2019. Kyverna Therapeutics, Inc. was incorporated in 2018 and is headquartered in Emeryville, California.
Over the last 12 months, insiders at Kyverna Therapeutics, Inc. have bought $0 and sold $0 worth of Kyverna Therapeutics, Inc. stock.
On average, over the past 5 years, insiders at Kyverna Therapeutics, Inc. have bought $20.02M and sold $0 worth of stock each year.
There was no buying activity among insiders over the last 12 months.
The last purchase of 910,000 shares for transaction amount of $20.02M was made by GILEAD SCIENCES, INC. (10 percent owner) on 2024‑02‑12.
| GILEAD SCIENCES, INC. | 10 percent owner | 4126119 9.547% | $13.29M | 1 | 0 | <0.0001% |
$11,468,215 | 44 | 17.78% | $156.52M | |
$16,245,616 | 40 | 123.58% | $160.27M | |
$140,938,207 | 36 | 14.75% | $128.86M | |
$35,092,436 | 31 | 38.62% | $137.58M | |
$63,049,419 | 31 | 2.87% | $136.6M | |
$294,424,120 | 20 | 1.33% | $146.16M | |
$1,239,833 | 16 | 53.23% | $128.69M | |
$448,999,793 | 15 | -19.99% | $131.98M | |
$178,593,887 | 15 | -14.86% | $131.35M | |
$10,143,329 | 12 | 11.84% | $160.32M | |
$9,999,920 | 10 | -40.03% | $127.15M | |
$6,593,243 | 8 | 12.72% | $164.91M | |
$22,090,972 | 7 | -3.49% | $158.23M | |
$17,675,244 | 7 | 92.20% | $166.29M | |
$63,981 | 5 | -11.55% | $138.28M | |
$32,289,200 | 3 | -5.46% | $153.99M | |
$9,999,990 | 2 | 25.53% | $130.8M | |
Kyverna Therapeutics, Inc. Common Stock (KYTX) | $20,020,000 | 1 | -75.24% | $139.16M |
$300,016 | 1 | -50.33% | $144.23M |
| Increased Positions | 42 | +41.58% | 2M | +5.59% |
| Decreased Positions | 39 | -38.61% | 5M | -15.32% |
| New Positions | 16 | New | 609,644 | New |
| Sold Out Positions | 14 | Sold Out | 2M | Sold Out |
| Total Postitions | 104 | +2.97% | 29M | -9.73% |
| Vida Ventures Advisors, Llc | $10,315.00 | 10.52% | 4.52M | 0 | 0% | 2025-03-31 |
| Gilead Sciences, Inc. | $9,408.00 | 9.6% | 4.13M | +4M | New | 2024-12-31 |
| Bain Capital Life Sciences Investors, Llc | $7,680.00 | 7.83% | 3.37M | 0 | 0% | 2024-12-31 |
| Northpond Ventures, Llc | $7,422.00 | 7.57% | 3.26M | 0 | 0% | 2024-09-30 |
| Jpmorgan Chase & Co | $4,939.00 | 5.04% | 2.17M | -220,915 | -9.25% | 2024-12-31 |
| Novo Holdings A/S | $4,218.00 | 4.3% | 1.85M | 0 | 0% | 2024-12-31 |
| Blackrock, Inc. | $3,822.00 | 3.9% | 1.68M | +3,775 | +0.23% | 2025-03-31 |
| Vanguard Group Inc | $2,994.00 | 3.05% | 1.31M | +306,525 | +30.45% | 2024-12-31 |
| Insight Holdings Group, Llc | $2,081.00 | 2.12% | 912,915 | 0 | 0% | 2024-12-31 |
| Millennium Management Llc | $1,702.00 | 1.74% | 746,521 | -507,035 | -40.45% | 2024-12-31 |